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Abstract The objective of this study was to compare the efficacy and safety of the second controller medications
(long-acting b2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler
corticosteroid treatment inmoderate persistent asthma.Atotal of 64 patientswith asthma, in themoderate persistent
asthma category, were divided into three groups. Patients, all of whomwere concurrently using inhaled corticosteroid
(Budesonide 400 mg twice daily), were treated for 3 monthswith either inhaled formoterol 9 mg twice daily (firstgroup),
oralzafirlukast 20mgtwice daily (secondgroup), or sustained-releasetheophylline 400mgoncedaily (thirdgroup).Allof
the patients were subjected to assessments on the subject of peak expiratory flow (PEF) variability, forced expiratory
volume in1sec (FEV1), asthma symptom scores (daytime andnight-time), supplemental terbutalin use, asthma exacerba-
tions and adverse events over the 3-month treatment period. In all of the three groups, significant improvementswere
recordedinthe lung function, asthma symptom scores and supplemental terbutalinuse criteria, as a resultoftreatments
applied.Formoterol treatment resulted in significantly greater and earlier improvements comparedwith the other two
groups in several criteria: PEF variability (17?972?5; 21?973?2; 23?773?3; Po0?001); asthma symptom score (daytime)
(1?670?5; 1?970?5; 2?070,5; Po0?05); asthma symptom score (night-time) (1?270?4; 2?270?5; 1?870?6; Po0?001);
and supplemental terbutalin use (1?270?3; 1?870?5; 1?770?5; Po0?05).However, at the end of the treatment, in all of
the three groups studied, improvementswere attained in overall asthma control and therewas no statistical difference
among the groups. Although there were no side effects which required the discontinuation of the treatment, it was
observed that the maximum side effect was in the second group (20%, 31?6% and 20%, respectively). In conclusion, in
patients who still have symptoms on treatment with inhaled corticosteroids, the addition of a long-acting b2-agonist,
leukotriene antagonists or sustained-release theophylline to the treatment is a logical approach, and, in addition to
inhaled corticosteroids, any one of these second controller medications may be chosen in patients with moderate
asthma.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1282, available online athttp://www.idealibrary.comon
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In the treatment of asthma, which is a chronic in£amma-
tory disease, currently themost e¡ective anti-in£amma-
tory agents used are the inhaled corticosteroids (1).
However, the symptoms of the patients are sometimes
not optimally controlled by inhaled corticosteroid alone
and there are side e¡ects of high-dosage oral or inhaled
corticosteroids. These situations result in a lack of har-
mony and trust in the treatment in the asthmatic
patients. In moderate persistent asthma in particular,Received12 September 2001and accepted in revised form12December
2001.Correspondence should addressed to: Ahmet SelimYurdakul,Tlp
Fak lˇtesi Cad.Balaban Sok.No: 24/11Abidinpas,a, Ankara,Turkey.Fax:
+90 312 355 2110; E-mail: ahmetselimyurdakul@hotmail.comthe objective of asthma treatment is not entirely ful¢lled
with inhaled corticosteroid (moderate or high dosage)
alone and keeping the illness under control becomes
more di⁄cult. For this reason, without increasing the
dosage of inhaled corticosteroid, it is proposed that
long-acting b2-agonist, leukotriene receptor antagonist
and sustained-release theophylline are used together in
addition to inhaled corticosteroids (2^4). However, on
the subject of using these drugs together with inhaled
corticosteroids, there are very few data that compare
control therapies and therefore, the bene¢ts of these
drugs within an asthma management program are not
very clear yet.Guidelines on asthma management, long-
acting b2-agonist, leukotriene receptor antagonist and
sustained-release theophylline are indicated among the
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mine the e⁄cacy of these drugs in treatment of asthma,
there is a need to perform comparative clinical studies.
For this reason, we designed a study to compare the
e⁄cacyof three di¡erent treatmentprotocols inmoder-
ate persistent asthma.Morning and evening peak expira-
tory £ow (PEF) values, PEF variability, forced expiratory
volume in 1sec (FEV1) values, asthma symptom scores
(daytime and night-time), supplemental terbutalin use,
asthma exacerbations and adverse events were deter-
mined in the initial, ¢rst month, second month and end
of the treatment (thirdmonth) periods.
PATIENTSANDMETHODS
A total of 64 patients de¢ned as havingmoderate persis-
tent asthma according to the criteria of the American
Thoracic Association (5) andCurrentNational Institutes
of Health Expert Panel Report 2 treatment guidelines of
theNational Asthma Education and Prevention Program
(3) were enrolled in the study. All of the patients were
previously using inhaled corticosteroid (moderate or
high dose) and short-acting b2-agonist for at least one
and half months prior to study. Forty-three of them had
moderate doses (Budesonide 800mg a day or equivalent
doses of beclomethasone dipropionate or £uticasone
propionate) and the others had higher doses (more than
budesonide 800mg a day or equivalent doses of beclo-
methasone dipropionate or £uticasone propionate). De-
spite treatment with inhaled corticosteroid, patients
continued to display symptoms. A reversibility test
(increase in FEV1of at least15 % frombaseline) was posi-
tive in all patients. After a run-in period of ten days,
eligible patients were randomized to each treatment
group in rows according to their application month to
hospital. To these groups the following three di¡erent
treatment combinations were applied:
First group (n=25): inhaled corticosteroid (Budesonide
400mg twice daily) + long-acting b2- agonist (Formoter-
ol 9mg twice daily);
Secondgroup (n=19): inhaled corticosteroid (Budesonide
400mg twice daily) + leukotriene receptor antagonist
(Za¢rlukast 20 mg twice daily);
Third group (n=20): inhaled corticosteroid (Budesonide
400mg twice daily) + sustained-release theophylline
(400mg once daily).
Furthermore, patients were given short-acting b2-
agonist (terbutalin) inhaler as needed. Concurrent use
of any medications that could interact with the drugs
used in the groups was not allowed. Since bioavailability
of za¢rlukast is reduced by food (6), patients were told
to take this drug 1h before or 2h after meals. Patients
were excluded if they had respiratory tract infection,
smoked cigarettes or had a respiratory disorder other
than asthma disease. All of the patients gave their in-formed consent spoken and witnessed, having been
informed about the details of the study. All of the
patientswere subjected to assessments of PEFvariability,
FEV1, asthma symptom scores (daytime and night-time),
supplemental terbutalin use, asthma exacerbations and
adverse events over the 3-month treatment period.
Patients used a hand-heldpeak £owmeter tomeasure
morning and evening PEF, recording the highest of three
forced exhalations in the morning immediately after
getting outof bed andbefore dosing with the study drug.
The evening measurement was also done in the same
manner before taking the drug. The following formula
was used to calculate the PEF variability (7,8):
PEF variability: Highest PEF valueLowest PEF value/
1/2 (Highest PEF value + Lowest PEF value) 100
In addition, patients regularly recorded daytime and
night-time asthma symptoms and supplemental terbuta-
lin use daily on diary cards. The daytime asthma symp-
tom score: 0 = no breathing problems at all, activity not
restricted; 1 = breathing problems with little or no dis-
comfort, and no activity restriction; 2 = breathing pro-
blemswith some discomfort, and limitation of strenuous
activity; 3 = breathing problems with discomfort and
limitation of routine activity; 4 = breathing problems at
rest with major discomfort and limitation in routine ac-
tivity.
Night-time asthma symptom score: 0 = no breathing
problems; 1 = one waking up because of breathing pro-
blems, but no use of rescue medication; 2 = one waking
up because of breathing problems, controlled by rescue
medication; 3 = more than one waking up because of
breathing problems, controlled by rescue medication; 4
= di⁄cult sleep because of breathing problems, despite
use of rescuemedication (9).
Spirometry was performed at each control period be-
fore themorning dose of trialmedication and the best of
three determinations of FEV1was recorded. In addition,
during this control period, patients were assessed with
respect to their harmony to the treatment, adverse
events, PEF instrument usage, keeping of daily cards in
an orderly manner, taking drugs regularly and in a cor-
rect manner and the asthma exacerbations. Patients
not obeying the study protocol and not observing asth-
ma exacerbations were withdrawn from the study. This
study was conducted in accordancewith theDeclaration
of Helsinki amended the 52nd WMA General Assembly
(Edinburgh, 2000).
Statistical analysis
Data processing and statistical analysis were performed
using GraphPad InStat (V2?04a). The sample size re-
quired for this study was calculated for the primary e⁄-
cacy end point, morning PEF, for the entire 3-month
treatment period. A sample size of 25, 20 or 19 patients
324 RESPIRATORYMEDICINEper groupwas su⁄cient to detect a signi¢cantdi¡erence
in morning PEF measurements at a signi¢cance level of
0?05 with a power of 80% using a two-sided signi¢cance
test. Secondary e⁄cacy endpoints included evening PEF,
variability in PEF, asthma symptom scores (daytime and
night-time), FEV1 and supplemental terbutalin use. All
data were expressed as means7 standard deviation. In
assessing the results in the treatment groups, one-way
analysis of variance (ANOVA) following by student^new-
man-keuls multiple comparisons test were used. A P
value of less than 0?05was accepted as statistically signif-
icant.
RESULTS
A total of 64 patients (43 women and 21 men) were
enrolled in this study. The demographic and baseline
disease characteristics are similar in the three groups
(Table1).
Lung function
In each of the threegroups, themorning and evening PEF
values were almost at the same level in the initial state
and there was no statistically signi¢cant di¡erence
among the groups (288?4 and 386 lmin1, respectively,
in the ¢rst group; 282?6 and 383?7 lmin1, respectively,
in the second group; 265 and 357?5 lmin1 respectively,
in the third group; P40?05). In all of the groups, in the
¢rstmonth of treatment, increases from baseline values
were noted in meanmorning and evening PEF.However,
in the ¢rst group, there was a signi¢cantly greater in-
crease in mean morning PEF (352 lmin1, 329?5 lmin1,
309 lmin1, respectively; Po0?01). In all of the three
groups, the increase in the morning and evening PEF
values continued during in the second and third month
of the treatment, but, there was no statistically signi¢-
cant di¡erence among the groups (P40?05).
There was no statistically signi¢cant di¡erence in
the baseline PEF variability values among the groups
(Table 2).When analyzed by treatment month, a signi¢-
cantly greater decrease in PEF variability was noted in
the ¢rst group than the other two groups after one
month of treatment (Po0?001). However, at the end ofTABLE 1. The demographic andbaseline disease characteristics
Groups (n=64) Sex (F/M) Ageyears FEV1 (% pre
1group (n=25) 17/8 38?376 66?67
2 group (n=19) 13/6 38?674 66?67
3 group (n=20) 13/7 37?777 65?27
Data are presented asmean7SD.M: male;F: female;FEV1: forthe secondmonth of the treatment, the decrease in PEF
variability in the ¢rst and secondgroupswas found to be
signi¢cantly greater compared with the third group
(Po0?05).Therewasno statistically signi¢cant di¡erence
between the ¢rst and second groups (P40?05) (Fig.1). In
the thirdmonth of the treatment, there was no statisti-
cally signi¢cant di¡erence in PEF variability among the
groups (P40?05).
The baseline mean FEV1values were similar in each of
the threegroups (Table 2). At the ¢rst and secondmonth
of the treatment, the increase in mean FEV1was signi¢-
cantly greater in the ¢rst and second groups compared
with thirdgroup (Po0?01).However, therewas no statis-
tically signi¢cantdi¡erencebetween the ¢rst and second
groups (P40?05). In the third month of the treatment,
there was no statistically signi¢cant di¡erence among
the groups (P40?05) (Fig. 2).
Asthma symptomscores
There was no statistically signi¢cant di¡erence among
the initial daytime symptom scores of the patients
(P40?05) (Table 2).When analyzedby treatmentmonth,
a signi¢cantly greater decrease in daytime symptom
scores was noted in the ¢rst group compared with the
other two groups after1month of treatment (Po0?05).
However, in each of the three groups, there was a de-
crease in daytime symptom scores compared with the
initial values (Po0?001) (Fig. 3).The decrease in symptom
score continued during the second and third months of
the treatment, but no statistically signi¢cant di¡erence
was observed among the groups (P40?05).
In the same manner, the initial night-time symptom
scores of the patients were almost at the same level and
there was no statistically signi¢cant di¡erence among
the groups (P40?05) (Table 2). After the treatment, in
each of the three groups there was a decrease in night-
time symptom scores from the initial values (Po0?05).
However, both in the ¢rst and the secondmonth of the
treatment, there was a signi¢cantly greater decrease in
the night-time symptom score in the ¢rst group com-
pared with the other two groups (Po0?001) (Fig. 4). In
the thirdmonth of the treatment, there was no statisti-
cally signi¢cant di¡erence among the three groups
(P40?05).dicted) PEF (morning) lmin1 PEF (evening) lmin1
4?8 288?4740?5 352747?1
4?4 282?6738?1 383?7747?4
6?1 265747?6 357?5755?4
ced expiratory volume in1sec;PEF: peakexpiratory £ow.
TABLE 2. Thevaluesof baseline andafter treatmentin PEF variability,FEV1 (% predicted), symptomscores (daytime andnight-
time), supplemental terbutalin use
Baseline 1month 2 months 3 months
PEF variability 1group 29?273?0 17?972?5 15?872?1 13?171?4
2 group 30?572?7 21?973?2 16?772?0 12?671?5
3 group 30?274?2 23?773?3 19?173?3 13?271?7
FEV1 (% predicted) 1group 66?674?8 81?3710?4 85?674?5 89?575?7
2 group 66?674?4 77?5711?9 85?975?9 87?375?7
3 group 65?276?1 70?874?3 80?375?2 86?675?8
Symptom score (daytime) 1group 3?070?5 1?670?5 1?070?7 0?570?5
2 group 3?070?5 1?970?5 1?170?5 0?670?5
3 group 3?170?4 2?070?5 1?370?6 0?770?5
Symptom score (night-time) 1group 2?570?5 1?270?4 0?670?6 0?270?4
2 group 2?770?5 2?270?5 1?170?5 0?470?5
3 group 2?770?5 1?870?6 1?170?7 0?370?5
Meannumberof rescue 1group 3?470?8 1?270?3 0?670?3 0?270?1
inhalations 2 group 3?870?7 1?870?5 1?170?4 0?370?1
3 group 3?670?8 1?770?5 1?070?4 0?270?1
Dataarepresentedasmean7SD.PEF denotespeakexpiratory £ow, and FEV1 (%predicted): forcedexpiratory volumeinone
second.
FIG. 1. Mean (7SD) the variability in PEF values at baseline and
treatmentmonths1through 3 in the three groups given second
controllermedications in additional to inhaled corticosteroid. (*)
represents signi¢cant di¡erence compared with za¢rlukast
(Po0?05), (+) represents signi¢cant di¡erence compared with
theophylline (Po0?05). Formoterol, &; Za¢rlukast, &;Theo-
phylline, .
FIG. 2. Mean (7SD) FEV1 (% predicted) values at baseline and
treatmentmonths1through 3 in the three groups given second
controller medications in additional to inhaled corticosteroid.
(+) represents signi¢cant di¡erence compared with theophyl-
line (Po0?05).Formoterol,&; Za¢rlukast,&;Theophylline, .
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When analyzed by treatment month, both in the ¢rst
and the secondmonth of the treatment there was a sig-
ni¢cantly greater decrease in the number of rescue ter-
butalin inhalations taken daily in the ¢rst group
compared with the other two groups (Po0?05) (Fig. 5).
And also, in second and third groups, there was a statis-
tically signi¢cantdecreasein the supplementalb2-agonistuse compared with the baseline values (Po0?05). How-
ever, there was no statistically signi¢cant di¡erence be-
tween each of these groups (P40?05) (Table 2). In the
third month of the treatment, there was no statistically
signi¢cant di¡erence among the three groups (P40?05).
Adverse events
The percentage of the patients reporting at least one
adverse event in each of the three groups was 20%,
FIG. 3. Mean (7SD) asthma symptom score for the day at
baseline and treatmentmonths1 through 3 in the three groups
given second controllermedications in additional to inhaled cor-
ticosteroid. (*) represents signi¢cant di¡erence comparedwith
za¢rlukast (Po0?05), (+) represents signi¢cantdi¡erence com-
paredwith theophylline (Po0?05).Formoterol,&; Za¢rlukast,
&;Theophylline, .
FIG. 4. Mean (7SD) asthma symptom score for the night at
baseline and treatmentmonths1 through 3 in the three groups
given second controllermedications in additional to inhaled cor-
ticosteroid. (*) represents signi¢cant di¡erence comparedwith
za¢rlukast (Po0?05), (+) represents signi¢cantdi¡erence com-
paredwith theophylline (Po0?05).Formoterol,&; Za¢rlukast,
&;Theophylline, .
FIG. 5. Mean (7SD) number of rescue terbutaline inhalations
taken daily at baseline and treatmentmonths1through 3 in the
threegroupsgivensecondcontrollermedicationsin additionalto
inhaledcorticosteroid. (*) represents signi¢cantdi¡erence com-
pared with za¢rlukast and theophylline (Po0?05). Formoterol,
&; Za¢rlukast,&;Theophylline, .
326 RESPIRATORYMEDICINE31?6% and 20%, respectively. The most frequently
reported adverse events were headache (8%,
10?5% and 10%, respectively) and dyspeptic com-
plaints (8%, 21?1% and 10%, respectively). There was
no asthma exacerbation in the group of patients included
in our study.DISCUSSION
The growth in understanding of the pathophysiology of
asthma and themechanisms by which anti-asthma drugs
acthasprovidedimportant insights into how thesedrugs
can be usedmost e¡ectively in the treatment of the un-
derlying in£ammation.The objectives of e¡ective asthma
management are to prevent chronic or frequently recur-
ring symptoms, to maintain normal pulmonary function
andnormal activity levels and to preventrecurrent acute
exacerbations of asthma (3). To attain these objectives,
among the controller medications inhaled corticoster-
oids are the most e¡ective anti-in£ammatory agents (1).
However, especially in moderate persistent asthma, the
objectives of the treatment of asthma are sometimes
not fully ful¢lled with inhaled steroid treatment alone.
In such cases, there are two alternatives: to increase in-
haled corticosteroid dosage or to add a second control-
ler medication to the treatment (3,9). High doses of
corticosteroid lead to a progressive increase in the risk
of adverse events (10), but avoidance of adverse e¡ects
from asthma medications is an objective of the asthma
treatment.The administration of combined drugs having
di¡erent e¡ectmechanisms can fullymeet the objectives
of asthma treatment. However, it is a matter under dis-
cussion which one of the second controller medications
should be used in combination with inhaled corticoster-
oids.
For this purpose, in addition to inhaled corticoster-
oids, we clinically investigated the e⁄cacy of the three
di¡erent controller medications proposed in the treat-
ment of asthma. In our study, the use of three di¡erent
controller medications in combination with inhaled
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tom scores and supplemental b2-agonist use. However,
it was observed that addition of a long-acting b2-agonist
to an inhaled corticosteroid provided signi¢cantly great-
er and earlier improvement than leukotriene receptor
antagonist and sustained-release theophylline in overall
asthma control. Busse and coworkers (11) demonstrated
that long-acting b2-agonist was more e¡ective than leu-
kotriene receptor antagonist in the overall asthma con-
trol. In other studies, it was observed that addition of a
long-acting b2-agonist to the treatment results in better
asthma control, instead of increasing inhaled corticos-
teroid dose in patients whose symptoms cannot be
controlled with moderate doses of inhaled corticoster-
oids (9,12^14). Indeed, to avoid side e¡ects that may
result from high-doses of inhaled corticosteroid treat-
ment and by adding a long b2-agonist to the treatment
as the second controllermedication is a logical approach.
It is suggested in the International Asthma Guidelines
(1,3,15), because long-acting b2-agonists relax airway
smooth muscle, enhance mucociliary clearance, inhibit
allergen-induced early and late asthmatic responses,
decrease vascular permeability, and inhibit secretor
functions of mast cells and eosinophils (1). However, it is
indicated that using long-acting b2-agonists for a long
timewill result in the development of a tolerance against
its own e¡ect and will mask in£ammation in respiratory
tract (16^18). There are studies that defend both views.
Pauwels and coworkers showed that using formoterol
andbudenoside together for a long time in the treatment
of asthma did not increase respiratory tract in£amma-
tion (14). No asthma exacerbation was observed in any
of the patients enrolled in our study. Besides, the
addition of a long-acting b2-agonist to treatment with
inhaled corticosteroid increases the quality of life by
decreasing the requirement of short-acting b2-agonist
(9). It was observed that regular treatment with a long-
acting b2-agonist has producedno reduction in broncho-
dilator e¡ect and worsened bronchial responsiveness
(19,20). In our study, the patient group using a long-acting
b2-agonist plus inhaled corticosteroid was observed to
have the least adverse e¡ects (headache 8%, dyspeptic
complaints 8%).
In our study, the addition of leukotriene receptor
antagonist to inhaled corticosteroid resulted in impro-
vements in lung functions, symptom scores and supple-
mental b2-agonist use. This improvement was attained
in a longer time (at the end of the second month)
comparedwith the ¢rstgroup.However, treatmentwith
za¢rlukast provided greater improvement than
sustained-release theophylline in the lung function.
Za¢rlukast is a selective and competitive inhibitor of
the cysteinyl leukotrienes LTC4, LTD4 and LTE4 (6). This
drug inhibits allergen-induced early and late asthmatic
responses (6,21), prevents exercise-inducedbronchocon-
striction (22) and is also e¡ective in aspirin-inducedasthma (2,23). In addition, it is observed that leukotriene
antagonists reduced eosinophils in the respiratory tract
of patients with asthma (24,25). In previous studies, it
was shown that the corticosteroid dosage could be de-
creased by adding leukotriene antagonists to treatment
in patients using higher doses of inhaled corticosteroids
(26^28). Besides, leukotriene antagonists provided im-
provements in lung functions, symptom scores and sup-
plemental b2-agonist use (29^31). The ¢ndings in our
study also conformed to the ¢ndings in the literature. In
the studies conducted, it is put forward that leukotriene
antagonists canhave an anti-in£ammatorye¡ect and can
prevent the need to increase the dose of inhaled corti-
costeroids (28^31). However, further clinical studies are
needed to establish their roles in asthma therapy. Also,
the group in which the most adverse events were ob-
served in our study is the group using leukotriene an-
tagonists plus inhaled corticosteroids (headache 10?5%,
dyspeptic complaints 21?1%). However, none of these
adverse events were su⁄cient to discontinue the
treatment of the patients.
According to the initial state of the treatment, the
addition of sustained-release theophylline to inhaled
corticosteroids provided less improvement in lung func-
tions than in the other two groups.However, treatment
with sustained-release theophylline only provided less
improvement than the ¢rstgroup in the symptom scores
and supplemental b2-agonist use parameters.Theophyl-
line was considered only to be a bronchodilator agent
before it was determined to be an anti-in£ammatory
agent in low serum concentrations (1,32,33), because this
drug prevents eosinophil in¢ltration to the bronchial
mucous and reduces release of mediators from
in£ammatory cells (34^37). In studies conducted, no dif-
ference is observed between the using low-dose inhaled
corticosteroids plus theophyllin and using only the high-
dose inhaled corticosteroids (38,39). International treat-
mentguidelines for the treatment of asthma also recom-
mend sustained-release theophylline, in patients not
using higher doses of inhaled corticosteroids (1,3). How-
ever, a general approach is to aim for a steady-state
serum concentration of theophylline of between
5^15mgml1 during long-term theophylline treatment.
For this reason, monitoring serum concentration is ad-
vised during treatment, and when conditions known to
alter theophylline metabolism exist (1,3), because there
are many side e¡ects dependent on dosage during theo-
phylline treatment, such as dyspeptic complaints, ar-
rhythmias and hypokalaemia (1,3). In our study, themost
frequently reported adverse events in theophylline
group were dyspeptic complaints and headache. We
could not monitor the serum theophylline concentra-
tions regulary in all of the patients, but the side e¡ects
of theophylline were explained to the patients and
attention was payed to factors a¡ecting theophylline
metabolism. Patients complaining of these side e¡ects
328 RESPIRATORYMEDICINEwere subjected to serum theophylline concentration
tests and they were found to be at the desired treatment
level. Therefore, the use of theophylline was not
discontinued.The combination of inhaledcorticosteroids
plus theophylline is substantially less expensive, as
compared with the other drugs combinations (38). This
is advantageous, but there are many factors that e¡ect
serum theophylline concentrations.
After three months’ study treatment, all of the
patients improved both clinically and in terms of their
laboratory results. After this period, we decreased the
dose of inhaled corticosteroid and then stopped the
second controller medications, but we could not include
these results because the patients were not all followed
up regularly.
The study was originally designed with four parallel
groups, one of which was only increasing the steroid
dosage. However, it was decided that this would not
ensure enough eligible patients for our study, because
many of our patient populations had no insurance and
¢nancial facility and also some of the eligible patients
were reluctant to give their informed consent. Multicen-
ter clinical studies are needed to clarify the e⁄cacy of
other alternatives such as cromoglycate/nedocromil or
increasing steroid doses and to investigate larger num-
bers of eligible patient populations.
In conclusion, in patients who still have asthma
symptoms on treatment with inhaled corticosteroids,
the addition of a long-acting b2-agonist, leukotriene
antagonists or sustained-release theophylline to the
treatment is a logical approach; and any one of these
second controllermedicationsmaybe chosen in patients
withmoderate asthma.
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